FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2279227967> ?p ?o ?g. }

• W2279227967 endingPage "e11072" @default.
• W2279227967 startingPage "e11072" @default.
• W2279227967 abstract "e11072 Background: Use of trastuzumab in the adjuvant and metastatic setting has been shown to improve outcomes (DFS and OS) in HER2+ patients. An earlier study found that 13% of HER2+ patients with stage II-III breast cancer did not receive trastuzumab. This study examined reasons HER2+ patients receiving adjuvant treatment did not get trastuzumab and examined HER2 testing patterns. Methods: Data and text fields of 12 community site EMRs were searched to identify patients believed to be HER2+ but with no record of trastuzumab treatment. Records from 1142 cases yielded 74 patients with invasive HER2+ disease but who were not treated with trastuzumab. For comparison, a random sample of 76 patients who did receive trastuzumab was identified. Chart extraction by experienced oncology nurses documented details of testing and reasons for non use of trastuzumab. Results: 95% of patients had documentation of IHC 3+ or FISH > 2.0. Treated patients were younger (53 vs. 66 yrs old), with later stage disease, larger tumor size, and a greater number of positive lymph nodes. The most common medical reasons for withholding trastuzumab were: small tumor size, negative nodes and early stage of disease (30%); advanced age (11%); and unspecified heart disease (5%). Patient reasons for declining trastuzumab included: declined systemic therapy or wanted hormonal treatment only (22%); perceived risk (11%); perceived lack of efficacy (8%); and cost (3%). There were no significant differences between patients who did or did not have documentation for non use (47%). Conclusions: In contrast to reports of inadequate HER2 testing based on administrative claims data, this detailed medical record review showed 95% correct testing. Oncologists treating patients for early-stage cancer appeared to follow testing and treatment guidelines. Although HER2+ implies high risk, older patients and those with smaller tumors and node negative disease were most likely to not receive trastuzumab. Documentation of medical reasons for not using trastuzumab was poor, but when provided was consistent with guidelines. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Genentech Genentech Genentech" @default.
• W2279227967 created "2016-06-24" @default.
• W2279227967 creator A5013269727 @default.
• W2279227967 creator A5034752937 @default.
• W2279227967 creator A5057115205 @default.
• W2279227967 creator A5072015843 @default.
• W2279227967 creator A5072563567 @default.
• W2279227967 creator A5085797478 @default.
• W2279227967 creator A5088532109 @default.
• W2279227967 date "2010-05-20" @default.
• W2279227967 modified "2023-09-27" @default.
• W2279227967 title "Testing procedures and reasons why HER2-positive breast cancer patients did not receive trastuzumab in the adjuvant setting." @default.
• W2279227967 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e11072" @default.
• W2279227967 hasPublicationYear "2010" @default.
• W2279227967 type Work @default.
• W2279227967 sameAs 2279227967 @default.
• W2279227967 citedByCount "0" @default.
• W2279227967 crossrefType "journal-article" @default.
• W2279227967 hasAuthorship W2279227967A5013269727 @default.
• W2279227967 hasAuthorship W2279227967A5034752937 @default.
• W2279227967 hasAuthorship W2279227967A5057115205 @default.
• W2279227967 hasAuthorship W2279227967A5072015843 @default.
• W2279227967 hasAuthorship W2279227967A5072563567 @default.
• W2279227967 hasAuthorship W2279227967A5085797478 @default.
• W2279227967 hasAuthorship W2279227967A5088532109 @default.
• W2279227967 hasConcept C121608353 @default.
• W2279227967 hasConcept C126322002 @default.
• W2279227967 hasConcept C143998085 @default.
• W2279227967 hasConcept C146357865 @default.
• W2279227967 hasConcept C151730666 @default.
• W2279227967 hasConcept C195910791 @default.
• W2279227967 hasConcept C2779134260 @default.
• W2279227967 hasConcept C2779786085 @default.
• W2279227967 hasConcept C29456083 @default.
• W2279227967 hasConcept C530470458 @default.
• W2279227967 hasConcept C71924100 @default.
• W2279227967 hasConcept C86803240 @default.
• W2279227967 hasConceptScore W2279227967C121608353 @default.
• W2279227967 hasConceptScore W2279227967C126322002 @default.
• W2279227967 hasConceptScore W2279227967C143998085 @default.
• W2279227967 hasConceptScore W2279227967C146357865 @default.
• W2279227967 hasConceptScore W2279227967C151730666 @default.
• W2279227967 hasConceptScore W2279227967C195910791 @default.
• W2279227967 hasConceptScore W2279227967C2779134260 @default.
• W2279227967 hasConceptScore W2279227967C2779786085 @default.
• W2279227967 hasConceptScore W2279227967C29456083 @default.
• W2279227967 hasConceptScore W2279227967C530470458 @default.
• W2279227967 hasConceptScore W2279227967C71924100 @default.
• W2279227967 hasConceptScore W2279227967C86803240 @default.
• W2279227967 hasIssue "15_suppl" @default.
• W2279227967 hasLocation W22792279671 @default.
• W2279227967 hasOpenAccess W2279227967 @default.
• W2279227967 hasPrimaryLocation W22792279671 @default.
• W2279227967 hasRelatedWork W2066747782 @default.
• W2279227967 hasRelatedWork W2329589776 @default.
• W2279227967 hasRelatedWork W2560406314 @default.
• W2279227967 hasRelatedWork W2593475799 @default.
• W2279227967 hasRelatedWork W2751941543 @default.
• W2279227967 hasRelatedWork W2896532861 @default.
• W2279227967 hasRelatedWork W2934076975 @default.
• W2279227967 hasRelatedWork W4242374293 @default.
• W2279227967 hasRelatedWork W4322772378 @default.
• W2279227967 hasRelatedWork W2342209702 @default.
• W2279227967 hasVolume "28" @default.
• W2279227967 isParatext "false" @default.
• W2279227967 isRetracted "false" @default.
• W2279227967 magId "2279227967" @default.
• W2279227967 workType "article" @default.